No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Paulson & Co Takes New Stake in Honeywell in Q1
Promising Phase III Trial Results Support Buy Rating for Madrigal Pharmaceuticals
Citi Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $456
Uncertainties and Data Gaps Lead to Sell Rating for Madrigal Pharmaceuticals' Rezdiffra
Express News | Madrigal Pharmaceuticals: 65% Of Patients With Clinically Significant Portal Hypertension at Baseline Moved Into Lower Risk Categories by Year Two
Express News | Madrigal Pharmaceuticals Inc - Rezdiffra Well-Tolerated With Low Discontinuation Rate